Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 3/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | GABBR2 | O75899 | 4/20 | 0.44 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | DRD3 | P35462 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19067150 | 1.00 | CYP2C9 (0.46) | CYP2C9KMT2AMEN1CYP2D6CYP2C19 | |
| SCHEMBL21271443 | 1.00 | CYP2C9 (0.46) | CYP2C9KMT2AMEN1CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL19067193 | 0.98 | CYP2C9 (0.45) | CYP2C9KMT2AMEN1CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL6776358 | 0.98 | CYP2C9 (0.45) | CYP2C9KMT2AMEN1CYP2D6CYP2C19 | |
| SCHEMBL19067182 | 0.88 | CYP2C9 (0.41) | CYP2C9KMT2AMEN1CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL19949352 | 0.86 | CYP2C9 (0.40) | CYP2C9KMT2AMEN1CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL19067170 | 0.86 | CYP2C9 (0.40) | CYP2C9KMT2AMEN1CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL19949380 | 0.86 | KMT2A (0.40) | CYP2C9KMT2AMEN1CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL19949351 | 0.86 | CYP2C9 (0.40) | CYP2C9KMT2AMEN1CYP2D6CYP2C19 | |
| Hydrochloric Acid SCHEMBL19949381 | 0.86 | KMT2A (0.40) | CYP2C9KMT2AMEN1CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | RAPPTA THERAPEUTICS OY (FI) | 2024-05-30 | — | — | US | disclosed |
| EP-3538526-B1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-04-10 | — | — | EP | disclosed |
| EP-4288412-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | Rappta Therapeutics Oy (FI) | 2023-12-13 | — | — | EP | disclosed |
| CN-111433207-B | As alpha V Pyrrolopyrazine derivatives of integrin inhibitors | 百时美施贵宝公司 | 2023-07-25 | — | — | CN | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-05-02 | — | — | US | disclosed |
| CN-110139864-B | Pyrrole amides as alpha V integrin inhibitors | 百时美施贵宝公司 | 2022-08-23 | — | — | CN | disclosed |
| CN-110167933-B | As αVAzole amides and amines as integrin inhibitors | 百时美施贵宝公司 | 2022-06-21 | — | — | CN | disclosed |
| CN-110167934-B | Cyclobutane-and azetidine-containing monocyclic and spiro compounds as alpha V integrin inhibitors | 百时美施贵宝公司 | 2022-06-10 | — | — | CN | disclosed |
| WO-2011073340-A1 | LABELLED INTEGRIN BINDERS | GE HEALTHCARE LIMITED (GB) | 2011-06-23 | — | — | WO | disclosed |
| US-6831199-B1 | In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 | G. D. SEARLE & CO. | 2004-12-14 | — | — | US | disclosed |
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | DRUG INNOVATION & DESIGN, INC. | 2003-07-24 | — | — | US | disclosed |
| EP-1255567-A1 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | Drug Innovation & Design, Inc. (US) | 2002-11-13 | — | — | EP | disclosed |
| CN-1085980-C | Meta-guanidino, ureido, thioureido or azacyclic aminobenzoic acid derivatives as integrin antagonists | SEARLE & CO (US) | 2002-06-05 | — | — | CN | disclosed |
| EP-0850221-B1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2001036003-A2 | SELECTIVE CELLULAR TARGETING: MULTIFUNCTIONAL DELIVERY VEHICLES | DRUG INNOVATION & DESIGN, INC. (US) | 2001-05-25 | — | — | WO | disclosed |
| US-6028223-A | AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS | G. D. SEARLE & CO. (US) | 2000-02-22 | — | — | US | disclosed |
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030138432-A1 | Selective cellular targeting: multifunctional delivery vehicles, multifunctional prodrugs, use as antineoplastic drugs | PAICS, ABCB1, ABCG2 | CYP2C9 545/4885KMT2A 2336/4885MEN1 2448/4885 |
| US-20240174603-A1 | MODULATORS OF PROTEIN PHOSPHATASE 2A (PP2A) AND METHODS USING SAME | PPM1A, PPP2CA, PPP3CA | CYP2C9 4632/4885KMT2A 1632/4885MEN1 3773/4885 |
| US-11639353-B2 | Cyclobutanes- and azetidine-containing mono and spirocyclic compounds as αV integrin inhibitors | ITGB1, ITGB2, ITGA1 | CYP2C9 914/4885KMT2A 3748/4885MEN1 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.